Screening of feature genes of the ovarian cancer epithelia with DNA microarray
© Ying et al.; licensee BioMed Central Ltd. 2013
Received: 23 April 2013
Accepted: 25 May 2013
Published: 5 June 2013
We aimed to screen differentially expressed genes (DEGs) of ovarian surface epithelia in order to provide beneficial help for early diagnosis and treatment of ovarian cancer with DNA microarrays.
We extracted the microarray expression profile GSE14407 from Gene Expression Omnibus database which conducted gene expression profiling analysis of 12 ovarian surface epithelia (OSE) and 12 laser capture microdissected serous ovarian cancer epithelia (CEPI) samples. The DEGs between OSE and CEPI were identified by Limma package of R language. Cluster analysis was employed to compare the differences of gene expression patterns between OSE and CEPI. Furthermore, DEGs were analyzed with Functional classification tool, GenMAPP software and GENECODIS.
We identified 1229 DEGs including 592 down-regulated genes and 637 up-regulated genes. Pathway analysis showed that cell cycle was the most significant pathway and the DEGs related with cell cycle were almost up-regulated. Module mining analysis showed that the up-regulated DEGs were related with signal transduction while the down-regulated DEGs were related with lipid metabolism pathway and cytoskeletal structure.
The genes related with cell cycle, lipid metabolism and cytoskeletal structure may be the treatment targets for ovarian cancer.
KeywordsOvarian cancer Differentially expressed gene Cluster analysis Pathway analysis Module analysis Cell cycle
Ovarian cancer is the fifth most common cause of cancer deaths among women and is the leading cause of death from gynecological neoplastic disease . The average 5-year survival rate is approximately 40%; however, most ovarian cancers are diagnosed when the disease has progressed to the advanced stages III or IV. Patients with advanced disease (stages III and IV) have a significantly lower survival rate of only 10%–20% . A high percentage of mortality results from low diagnosis rate. Survival rates can approach 90% when ovarian cancer is diagnosed at an early stage; however, early detection is challenging, because the relatively nonspecific symptoms of ovarian lesions may be overlooked until abdominal distension by ascites fluid or by large tumor masses becomes unmistakable. Even with extensive surgical debulking and aggressive chemotherapy, the prognosis for women with ovarian cancer currently is not hopeful.
The conventional view is that approximately 90% of ovarian cancers are derived from the single-cell layer of surface epithelium that surrounds the ovary . As the ovarian epithelium transforms into a malignant phenotype, it differentiates into several subtypes that have been categorized into serous, mucinous, endometrioid and clear cell carcinoma, based on their morphology rather than their genotype . Epithelial ovarian cancers show a high degree of genetic heterogeneity as a result of mutations, silencing, and deletions. Since changes in gene expression, either through mutation, epigenetic regulation, or differential splicing events, influence tumor development, progression, drug responsiveness and ultimately the survival of the patient, the identification of the tumor subtype and its genetic fingerprint is essential. Several studies have indicated that different histological subtypes of ovarian carcinoma are associated with different causes and underlying mechanisms, including gene amplification, genetic predisposition, and various carcinogens . Nonetheless, the origin and causes of ovarian carcinoma remain to be elucidated.
The development of microarray technology has provided new insights into cancer diagnosis and treatment. Large-scale microarray studies in breast cancer have succeeded in clarifying 5 molecular subtypes based on gene expression profiles and in developing genomic biomarkers for predicting recurrence in early breast cancer . Thus, breast cancer treatment strategies are being stratified according to molecular characteristics. In contrast, there are no gene expression signatures with high accuracy and reproducibility for clinical diagnosis and management in patients with ovarian cancer because there is a paucity of ovarian cancer samples available for microarray analysis compared with breast cancer. Although TP53 somatic mutation is present in almost all high-grade serous ovarian cancer and plays an important role in the pathogenesis [7, 8], high-grade serous ovarian cancer exhibits much biological and molecular heterogeneity that should be considered when developing a novel therapeutic strategy for ovarian cancer [8, 9]. A better understanding of the molecular mechanisms leading to ovarian cancer may provide new opportunities for the development of strategies for diagnosis and therapy.
In the present study, we compared the gene expression profile between ovarian surface epithelia (OSE) and laser capture microdissected serous ovarian cancer epithelia (CEPI) samples. Differentially expressed genes (DEGs) were analyzed using gene ontology (GO), molecular pathway, and gene set enrichment analysis algorithms methods. Here we highlight progressive changes that lead to a highly dysregulated cell cycle. These genes, their gene products and the associated signaling pathways may represent novel targets for intervention of ovarian cancer progression.
Materials and methods
Source of data
We extracted the microarray expression profile from the study of Nathan J Bowen et al. , which was deposited in GEO (Gene Expression Omnibus) database under accession number GSE14407. This study conducted gene expression profiling analysis of 12 OSE and 12 CEPI samples on Affymetrix Human Genome U133 plus 2.0 Array.
Data preprocessing and DEGs analysis
The probe-level data in CEL files were converted into expression measures and the missing values were imputed . All the data were normalized before statistical analysis . Limma package  of R language was used to identify the DEGs between OSE and CEPI. P value was adjusted through the Benjamini and Hochberg procedure . A combination of false discovery rate (FDR) < 0.05 and the absolute value of logFc (Fold change) = 1 was used as the threshold to determine the significance of gene expression difference.
Comparing the difference of gene expression between OSE and CEPI according to their expression patterns
Cluster analysis for genome-wide expression data from DNA microarray hybridization uses standard statistical algorithms to arrange genes according to similarity in pattern of gene expression. The output is displayed graphically, conveying the clustering and the underlying expression data simultaneously in a form intuitive for biologists. We used cluster analysis for comparing the difference of gene expression patterns between OSE and CEPI samples.
Gene set enrichment analysis for DEGs
Individual gene analysis (IGA) evaluates the significance of individual genes (approved by Ethical Committee of Shengjing Hospital of China Medical University) between two groups of samples compared. The main problems of IGA originate from the use of the cutoff threshold value. First, the final result of IGA is significantly affected by the selected threshold, which is normally chosen arbitrarily. Second, many genes with moderate but meaningful expression changes are discarded by the strict cutoff value, which leads to a reduction in statistical power. Gene set analysis (GSA) methods free from the problems of the ‘cutoff-based’ methods. GSA directly scores pre-defined gene sets for differential expression and especially aims to identify gene sets with ‘subtle but coordinated’ expression changes that cannot be detected by IGA methods. The key principle is that even weak expression changes in individual genes gathered to a large gene set can show a significant pattern.
Functional Classification Tool used agglomerative clustering algorithm technique for mining the complex function of gene set . We analyzed the up-regulated genes and down-regulated genes separately with cluster method. FDR < 0.05 was set as threshold.
Pathway analysis for DEGs
GenMAPP  (Gene Map Annotator and Pathway Profiler) is a free, open-source, stand-alone application for visualizing, analyzing and sharing genome-scale data in the context of biological pathways. GenMAPP allows users to view and analyze genome-scale data, such as microarray data, on biological pathways, GO terms or any other grouping of genes. In the present study, GenMAPP was used to identify which pathways are affected by analyzing DEGs in ovarian cancers.
Module mining and function analysis for DEGs
Gene sets reflect biological modules only approximately. Only a subset of genes in a set may contribute to its expression signature, and different gene sets may have similar signatures across the arrays, owing to either an overlap between the gene sets or co-regulation of non-overlapping gene sets. When several gene sets (a cluster) have similar signatures, we extracted from this cluster a core module, which both refines the gene composition of each gene set and combines several related gene sets. This module more closely reflects the genes that participate in a specific biological process, as it consists of the genes whose expression profile corresponds to the signature of the cluster .
We used GeneCodis software to integrate DEGs to find groups of genes with similar biological meaning. GeneCodis , a web-based application, is a tool for singular and modular enrichment analysis that integrates information of diverse nature (e.g. functional, regulatory or structural) by looking for frequent patterns in the space of annotations and computing their statistical relevance. It can provide analysis of different annotations, including the three GO categories (biological process, cellular component, and molecular function), KEGG pathways, InterPro Motifs, and Swiss-Prot keywords. This integrative capacity sheds light on different aspects of the same information and provides a more accurate interpretation of the data.
We obtained publicly available microarray dataset GSE14407 from GEO database. After preprocessing and normalization, at the threshold of FDR < 0.05 and |logFC| > 1, we got 1229 DEGs which included 592 down-regulated genes and 1637 up-regulated genes.
Differential gene expression patterns between OSE cells and CEPI
Gene set enrichment analysis for DEGs
Pathway analysis for DEGs
Module mining and function analysis
Functional annotations for genes in modules A, B, C and D
G-protein signaling, coupled to cyclic nucleotide second messenger
Response to external stimulus
G-protein coupled receptor protein signaling pathway
Cell surface receptor linked signaling pathway
Response to chemical stimulus
Response to stimulus
G-protein signaling, coupled to cyclic nucleotide second messenger
G-protein coupled receptor protein signaling pathway
Cell surface receptor linked signaling pathway
Intermediate filament cytoskeleton organization
Intermediate filament-based process
Sphingolipid metabolic process
Membrane lipid metabolic process
Cellular lipid metabolic process
Sphingoid metabolic process
Lipid metabolic process
Phospholipid metabolic process
Organophosphate metabolic process
In the present study, we have identified genes and their functional categories that are altered in CEPI samples. The gene expression profiles displays statistically significant changes in cell cycle, signal pathway, metabolism and other functional categories that correspond well with many of the morphological changes and biological behaviors.
Dysregulation of the cell cycle is a hallmark of many cancers and control and timing of the cell cycle involves checkpoints and regulatory pathways that ensure the fidelity of DNA replication and chromosome segregation . These processes involve a large collection of key molecules, which are excellent candidates for ovarian cancer susceptibility variants. These include the cyclins (CCNA1, CCNA2, CCNB1, CCNB2, CCND1, CCND2, CCND3, CCNE1, CCNE2, CCNG1, CCNG2), cyclin-dependent kinases (CDKS: CDK1, CDK2, CDK4, CDK6, CDK7, CDC2), CDK inhibitors (CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D) and CDC2 regulators (CDC25A, CDC25B, CDC25C) . In the current study, CDK1, CDC6, CDC20, CDC25A, CDC25B, CDC25C, CDC45, Bub1, ORC6 were up-regulated. Studies have shown that up-regulation of CDC6, CDC 20, CDC25 family and Bub1 has relationship with human cancers.
Bub1 encodes a kinase involved in spindle checkpoint function. Several studies have found high Bub1 levels in subsets of breast and gastric cancers, and lymphomas. Furthermore, independent studies of diverse tumor types have identified Bub1 as a gene whose up-regulation correlates with poor clinical prognosis .
It is reported that Cdc20 functions as an oncoprotein to promote the development and progression of human cancers . Microarray studies have recently reported overexpression of CDC20 in various tumors, such as tumors of the oral cavity , stomach , brain (glioblastoma) , urinary bladder , uterine cervix , and ovary . Meta-analysis of cancer microarray data also identifies CDC20 as one of the highly expressed genes in various human cancer tissues . Furthermore, expressions of specific genes including CDC20 consistently correlate with total functional aneuploidy and are predictive of poor prognosis in several cancer types using a computational method . Particularly in serous epithelial ovarian cancer, overexpression of CDC20 is a prognostic factor associated with clinical stage of disease, irrespective of tumor grade .
The cell division cycle 25 (CDC25) families of proteins is a group of highly conserved dual-specificity phosphatases. There are three isoforms: CDC25A, CDC25B and CDC25C. They are key regulators of normal cell division and the cell response to DNA damage, and play a fundamental role in transitions between cell cycle phases during normal cell division, via the activation of CdK/cyclin complexes. Their abnormal expression, detected in a number of tumors, often correlated with a poor clinical prognosis, implies that their dysregulation is involved in malignant transformation . In the context of the progression of cell division, the A and B isoforms of CDC25 have been reported as potential oncogenes, being overexpressed in more than ten types of human cancer, including prostate and breast cancers, as well as vulvar squamous cell carcinomas. In contrast, CDC25C is expressed at a far lower level in a limited number of tumors .
Module analysis showed that the modules containing the down-regulated DEGs were related with lipid metabolic process and cytoskeletal structure. The modules containing up-regulated DEGs were related with signal transduction. In the last decade, the altered lipid metabolism has increasingly been recognized as another common property of malignant cells [31, 32]. Like glucose metabolism, lipid metabolism in cancer cells is also regulated by the common oncogenic signaling pathways, and is believed to be important for the initiation and progression of tumors . Some newly generated lipids molecules, such as phosphatidic acid (PA), diacylglycerol (DAG), and lysophosphatidic acid (LPA), also mediate signal transduction in cancer cells . These lipids regulate a variety of cellular functions including cell proliferation, survival and migration by either activating other signaling proteins inside the cells, or binding to a series of G protein-coupled receptors (GPCRs) on the cell surfaces. It has been reported that inhibitors of lipid metabolic pathways, particularly drugs targeting the mevalonate pathway, have been suggested to be valuable in enhancing the effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) . On the other hand, oncogenic signaling pathways can regulate lipid metabolism at multiple steps, including transcriptional, translational and post-translational levels.
The cytoskeleton plays an important role in tumor cell progression and events such as migration and invasion, allowing the cells to adapt and survive in different microenvironments; compounds that regulate cytoskeleton organization have been used as cancer therapeutics . On the other hand, the organization of the cytoskeleton affects cellular organization, adhesion complexes and polarity, and vesicular transports. Creekmore et al. demonstrate that cytoskeleton disorganization can have profound effects on the subcellular localization of important signaling intermediates, which ultimately may lead to modulated signaling pathways contributing to ovarian cancer development .
The complex molecular processes underlying the onset and development of epithelial ovarian cancer is only beginning to be unraveled. Our results indicate that cell cycles, lipid metabolic pathways, cytoskeleton changes and some signal transduction pathways are involved in the establishment and development of ovarian cancer. While many of these pathways have previously been either directly or indirectly implicated in ovarian cancer, detailed network analyses of our gene expression data led to the identification of linkages between these pathways attributable to the altered expression of key regulatory genes.
Our results indicate cell cycles, lipid metabolic pathways, cytoskeleton changes and some signal transduction pathways are involved in the establishment and development of ovarian cancer.
This study was supported by Liaoning Province Doctor Startup Fund of Natural Science Foundation (20071047). The Scientific Research Project of Higher Education Program of Liaoning Provincial Department of Education (2009A724) and Liaoning Science and Technology Project (2010225032).
- Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, Quackenbush J, Culhane AC: Stem cell-like gene expression in ovarian cancer predicts type ii subtype and prognosis. PLoS One 2013, 8: e57799. 10.1371/journal.pone.0057799PubMed CentralPubMedView ArticleGoogle Scholar
- Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M: MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int 2013, 2013: 241763.PubMed CentralPubMedView ArticleGoogle Scholar
- Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22: 255–288. 10.1210/er.22.2.255PubMedGoogle Scholar
- Creekmore AL, Silkworth WT, Cimini D, Jensen RV, Roberts PC, Schmelz EM: Changes in gene expression and cellular architecture in an ovarian cancer progression model. PLoS One 2011, 6: e17676. 10.1371/journal.pone.0017676PubMed CentralPubMedView ArticleGoogle Scholar
- Guo X, Liu G, Schauer IG, Yang G, Mercado-Uribe I, Yang F, Zhang S, He Y, Liu J: Overexpression of the beta subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis. Am J Patho 2011, 179: 1385–1393. 10.1016/j.ajpath.2011.05.018View ArticleGoogle Scholar
- Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, et al.: High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res 2012, 18: 1374–1385. 10.1158/1078-0432.CCR-11-2725PubMedView ArticleGoogle Scholar
- Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, et al.: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010, 221: 49–56. 10.1002/path.2696PubMed CentralPubMedView ArticleGoogle Scholar
- Bell D, Berchuck A, Birrer M, et al.: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474: 609–615. 10.1038/nature10166View ArticleGoogle Scholar
- Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al.: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008, 14: 5198–5208. 10.1158/1078-0432.CCR-08-0196PubMedView ArticleGoogle Scholar
- Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB, McDonald JF: Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics 2009, 2: 71. 10.1186/1755-8794-2-71PubMed CentralPubMedView ArticleGoogle Scholar
- Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, Botstein D, Altman RB: Missing value estimation methods for DNA microarrays. Bioinformatics 2001, 17: 520–525. 10.1093/bioinformatics/17.6.520PubMedView ArticleGoogle Scholar
- Fujita A, Sato JR, Rodrigues Lde O, Ferreira CE, Sogayar MC: Evaluating different methods of microarray data normalization. BMC Bioinformatics 2006, 7: 469. 10.1186/1471-2105-7-469PubMed CentralPubMedView ArticleGoogle Scholar
- Smyth GK: Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions using R and Bioconductor. Edited by: Gentleman VC R, Dudoit S, Irizarry R, Huber W. New York: Springer; 2005:397–420.View ArticleGoogle Scholar
- Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, Assa S, Karp M, Benjamini Y, Hochberg Y, Laron Z: Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995, 45: 486–490. 10.1016/0306-9877(95)90228-7PubMedView ArticleGoogle Scholar
- Da Huang W, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37: 1–13. 10.1093/nar/gkn923PubMedView ArticleGoogle Scholar
- Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR: GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 2002, 31: 19–20. 10.1038/ng0502-19PubMedView ArticleGoogle Scholar
- Guimera R, Nunes Amaral LA: Functional cartography of complex metabolic networks. Nature 2005, 433: 895–900. 10.1038/nature03288PubMed CentralPubMedView ArticleGoogle Scholar
- Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A: GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol 2007, 8: R3. 10.1186/gb-2007-8-1-r3PubMed CentralPubMedView ArticleGoogle Scholar
- Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, Schildkraut J, Berchuck A, Couch FJ, Wang X, et al.: Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer 2009, 101: 1461–1468. 10.1038/sj.bjc.6605284PubMed CentralPubMedView ArticleGoogle Scholar
- Ricke RM, Jeganathan KB, Van Deursen JM: Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation. J Cell Biol 2011, 193: 1049–1064. 10.1083/jcb.201012035PubMed CentralPubMedView ArticleGoogle Scholar
- Wang Z, Wan L, Zhong J, Inuzuka H, Liu P, Sarkar FH, Wei W, Wang Z, Wan L, Zhong J, Inuzuka H, Liu P, Sarkar FH, Wei W: Cdc20: a potential novel therapeutic target for cancer treatment. Curr Pharm Des 2013, 19: 3210–3214. 10.2174/1381612811319180005PubMed CentralPubMedView ArticleGoogle Scholar
- Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S: Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 2007, 28: 81–92. 10.1093/carcin/bgl100PubMedView ArticleGoogle Scholar
- Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO, Kim JH, Song KS, Rho SM, Yoo HS, Kim YS, et al.: Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 2005, 11: 473–482.PubMedGoogle Scholar
- Marucci G, Morandi L, Magrini E, Farnedi A, Franceschi E, Miglio R, Calo D, Pession A, Foschini MP, Eusebi V: Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 2008, 453: 599–609. 10.1007/s00428-008-0685-7PubMedView ArticleGoogle Scholar
- Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA: Identification of common differentially expressed genes in urinary bladder cancer. PLoS One 2011, 6: e18135. 10.1371/journal.pone.0018135PubMed CentralPubMedView ArticleGoogle Scholar
- Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G, Selvaluxmy G: Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer 2011, 11: 80. 10.1186/1471-2407-11-80PubMed CentralPubMedView ArticleGoogle Scholar
- Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006, 119: 599–607. 10.1002/ijc.21902PubMedView ArticleGoogle Scholar
- Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004, 101: 9309–9314. 10.1073/pnas.0401994101PubMed CentralPubMedView ArticleGoogle Scholar
- Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006, 38: 1043–1048. 10.1038/ng1861PubMedView ArticleGoogle Scholar
- Lavecchia A, Di Giovanni C, Novellino E: CDC25 phosphatase inhibitors: an update. Mini Rev Med Chem 2012, 12: 62–73. 10.2174/138955712798868940PubMedView ArticleGoogle Scholar
- Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11: 85–95.PubMedView ArticleGoogle Scholar
- Menendez JA, Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7: 763–777. 10.1038/nrc2222PubMedView ArticleGoogle Scholar
- Yano K: Lipid metabolic pathways as lung cancer therapeutic targets: a computational study. Int J Mol Med 2011, 29: 519–529.PubMed CentralPubMedGoogle Scholar
- Zhao Y, Fang WS, Pors K: Microtubule stabilising agents for cancer chemotherapy. Expert Opin Ther Pat 2009, 19: 607–622. 10.1517/13543770902775713PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.